4.02
-0.07(-1.71%)
Currency In USD
| Previous Close | 4.09 |
| Open | 4.15 |
| Day High | 4.32 |
| Day Low | 3.66 |
| 52-Week High | 100.8 |
| 52-Week Low | 3.55 |
| Volume | 55,211 |
| Average Volume | 141,311 |
| Market Cap | 9.7M |
| PE | -0.5 |
| EPS | -8.02 |
| Moving Average 50 Days | 4.58 |
| Moving Average 200 Days | 11.65 |
| Change | -0.07 |
If you invested $1000 in HCW Biologics Inc. (HCWB) since IPO date, it would be worth $676.06 as of August 18, 2025 at a share price of $4.259. Whereas If you bought $1000 worth of HCW Biologics Inc. (HCWB) shares 3 years ago, it would be worth $47.12 as of August 18, 2025 at a share price of $4.259.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
GlobeNewswire Inc.
Jun 27, 2025 11:45 AM GMT
Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated Presentation at the Phoenix Best Science Series b
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
GlobeNewswire Inc.
Jun 26, 2025 11:55 AM GMT
Company in full compliance for continued listingMIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developin
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
GlobeNewswire Inc.
Jun 04, 2025 12:20 PM GMT
HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical